For monitoring therapy response in CML, it is of outmost importance to be able to quantify also very low levels of BCR-ABL1 positive cells, also to get an early indication of increasing BCR-ABL1 levels and an impending relapse. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.